Riccardo Carloni

465 total citations
17 papers, 342 citations indexed

About

Riccardo Carloni is a scholar working on Oncology, Surgery and Hepatology. According to data from OpenAlex, Riccardo Carloni has authored 17 papers receiving a total of 342 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Surgery and 4 papers in Hepatology. Recurrent topics in Riccardo Carloni's work include Pancreatic and Hepatic Oncology Research (11 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers). Riccardo Carloni is often cited by papers focused on Pancreatic and Hepatic Oncology Research (11 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers). Riccardo Carloni collaborates with scholars based in Italy, Türkiye and France. Riccardo Carloni's co-authors include Giovanni Brandi, Alessandro Rizzo, Alessandro Di Federico, Andrea De Giglio, Andrea Palloni, Giorgio Frega, Mariacristina Di Marco, Émilie Béquignon, M. Juliéron and Barbara Hersant and has published in prestigious journals such as Journal of Clinical Oncology, BMC Cancer and Cancers.

In The Last Decade

Riccardo Carloni

16 papers receiving 339 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Riccardo Carloni Italy 6 148 117 66 62 58 17 342
Gilles van Tienderen Netherlands 8 192 1.3× 106 0.9× 161 2.4× 54 0.9× 62 1.1× 12 421
Jesse Lee United States 12 62 0.4× 92 0.8× 40 0.6× 61 1.0× 44 0.8× 24 366
Attila Bursics Hungary 12 192 1.3× 175 1.5× 46 0.7× 111 1.8× 21 0.4× 38 435
Filippos Kontos United States 8 252 1.7× 87 0.7× 32 0.5× 51 0.8× 16 0.3× 15 429
Ryoya Yamaoka Japan 11 76 0.5× 184 1.6× 76 1.2× 46 0.7× 90 1.6× 25 349
Sara Shamdani France 11 36 0.2× 114 1.0× 38 0.6× 53 0.9× 45 0.8× 15 344
Chuang Cai China 10 49 0.3× 57 0.5× 22 0.3× 41 0.7× 35 0.6× 15 314
Nian‐Nian Zhong China 13 107 0.7× 47 0.4× 51 0.8× 44 0.7× 11 0.2× 36 331
Alexander Dewerth Germany 10 53 0.4× 45 0.4× 67 1.0× 30 0.5× 37 0.6× 14 401
Masaaki Onaga Japan 6 89 0.6× 74 0.6× 38 0.6× 54 0.9× 201 3.5× 9 411

Countries citing papers authored by Riccardo Carloni

Since Specialization
Citations

This map shows the geographic impact of Riccardo Carloni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Riccardo Carloni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Riccardo Carloni more than expected).

Fields of papers citing papers by Riccardo Carloni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Riccardo Carloni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Riccardo Carloni. The network helps show where Riccardo Carloni may publish in the future.

Co-authorship network of co-authors of Riccardo Carloni

This figure shows the co-authorship network connecting the top 25 collaborators of Riccardo Carloni. A scholar is included among the top collaborators of Riccardo Carloni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Riccardo Carloni. Riccardo Carloni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Carloni, Riccardo, Alessandro Rizzo, Angela Dalia Ricci, et al.. (2023). Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. Volume 10. 1445–1463. 9 indexed citations
2.
Carloni, Riccardo, Alessandro Rizzo, Angela Dalia Ricci, et al.. (2022). Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine. Translational Oncology. 25. 101514–101514. 16 indexed citations
3.
Carloni, Riccardo, Alessandro Rizzo, Angela Dalia Ricci, et al.. (2022). Dual Immune Checkpoint Blockade in Hepatocellular Carcinoma: Where do we Stand?. Future Oncology. 18(8). 1023–1034. 4 indexed citations
4.
Federico, Alessandro Di, Riccardo Carloni, Giorgio Frega, et al.. (2022). Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. Cancers. 14(10). 2429–2429. 73 indexed citations
5.
Rizzo, Alessandro, Riccardo Carloni, Angela Dalia Ricci, et al.. (2022). Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis. Expert Opinion on Drug Safety. 22(4). 323–329. 5 indexed citations
6.
Rizzo, Alessandro, Riccardo Carloni, Giorgio Frega, et al.. (2022). Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center. Current Oncology. 29(7). 5084–5090. 4 indexed citations
7.
Carloni, Riccardo, Alessandro Rizzo, Antonio Cusmai, et al.. (2022). Advances in Novel Systemic Therapies for Advanced Hepatocellular Carcinoma. Future Medicinal Chemistry. 14(20). 1455–1470. 2 indexed citations
8.
Rizzo, Alessandro, Massimiliano Salati, Giorgio Frega, et al.. (2022). Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study. Medicina. 58(11). 1543–1543. 5 indexed citations
9.
Rizzo, Alessandro, Riccardo Carloni, Angela Dalia Ricci, et al.. (2022). Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis. Journal of Personalized Medicine. 12(8). 1247–1247. 5 indexed citations
10.
Federico, Alessandro Di, Valentina Tateo, Claudia Parisi, et al.. (2021). Hacking Pancreatic Cancer: Present and Future of Personalized Medicine. Pharmaceuticals. 14(7). 677–677. 39 indexed citations
11.
Federico, Alessandro Di, et al.. (2021). Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. Expert Opinion on Investigational Drugs. 31(4). 361–369. 81 indexed citations
12.
Marco, Mariacristina Di, Riccardo Carloni, Stefania De Lorenzo, et al.. (2020). Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report. World Journal of Gastrointestinal Oncology. 12(12). 1456–1463. 2 indexed citations
13.
Carloni, Riccardo, Stefania De Lorenzo, Elisa Grassi, et al.. (2020). Aggressive approach to metastatic pancreatic cystadenocarcinoma in a patient harboring BRCA-1 germline mutation: a case report.. Pancreatology. 20. S149–S150.
14.
Marco, Mariacristina Di, Riccardo Carloni, Stefania De Lorenzo, et al.. (2020). Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report. World Journal of Clinical Cases. 8(7). 1241–1250. 4 indexed citations
15.
Ricci, Claudio, Riccardo Carloni, Elisa Grassi, et al.. (2020). Intraoperative electrochemotherapy in locally advanced pancreatic cancer: Results and impact on quality of life. a single center experience.. Journal of Clinical Oncology. 38(15_suppl). e16731–e16731. 1 indexed citations
16.
Grassi, Elisa, Andrea Palloni, Riccardo Carloni, et al.. (2020). Searching for novel multimodal treatments in oligometastatic pancreatic cancer. BMC Cancer. 20(1). 271–271. 5 indexed citations
17.
Bosc, Romain, Barbara Hersant, Riccardo Carloni, et al.. (2016). Mandibular reconstruction after cancer: an in-house approach to manufacturing cutting guides. International Journal of Oral and Maxillofacial Surgery. 46(1). 24–31. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gilles van Tienderen Breakdown of academic impact, for papers by Jesse Lee Breakdown of academic impact, for papers by Attila Bursics Breakdown of academic impact, for papers by Filippos Kontos Breakdown of academic impact, for papers by Ryoya Yamaoka Breakdown of academic impact, for papers by Sara Shamdani Breakdown of academic impact, for papers by Chuang Cai Breakdown of academic impact, for papers by Nian‐Nian Zhong Breakdown of academic impact, for papers by Alexander Dewerth Breakdown of academic impact, for papers by Masaaki Onaga
Rankless by CCL
2026